ARS Pharmaceuticals (SPRY) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.36
- Estimate
- -$0.33
- Surprise
- -8.0%
- Revenue (period 2026-09-30)
- $37.7M
- Score today
- 5.8/10
Revenue source: xbrl.
How the report landed
ARS Pharmaceuticals (SPRY) reported a wider loss than forecast — adjusted EPS of -$0.36 against the -$0.33 estimate (a 8.0% shortfall).
Coverage in the report window
- Cantor Fitzgerald Maintains Overweight Rating on ARS Pharmaceuticals — fiscal.ai, 2026-11-06
- Raymond James Downgrades ARS Pharmaceuticals to Outperform — fiscal.ai, 2026-11-06
- ARS Pharmaceuticals Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-06
Where TrendMatrix's rating stands now
TrendMatrix currently rates SPRY Hold at 5.8/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -8.0% surprise compares with a -3.2% four-quarter average. Next scheduled report: 2027-03-09.
What argues against it
- Concentration risk — Pipeline: neffy
- DATA_ISSUE: analyst_target_implausible (raw $24.33 vs price $2.79 — ratio 8.7×). Rejected, falling back to technical TP.
- Market cap $277M below $400M minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $2.79
- Price target
- $4.35
- Stop
- $2.59
- Upside to target
- +55.9%
Risk check: RSI 16 — a level conventionally read as oversold; trading volume is running 2.7× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.
SPRY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $277.5M
- P/E (fwd)
- -3.1
- 52-week range
- $2.44–$13.15
- Off 52-week high
- 78.8%
- RSI (14)
- 16
- Volume vs avg
- 2.74×
- Score today
- 5.8/10